Individual pathological, clinical, MRI, and PET-MET data
Patient no | Clinical data | MRI data | PET-MET data | Pathological data | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sex | Age | Age at epilepsy onset (years) | Epilepsy duration (years) | Location | Side | Gadolinium enhancement | Tumour size (best diameter) in mm | Visual methionine uptake | Mean T/C | Max T/C | OR | Camera | ||
DNT, dysembryoplastic neuroepithelial tumour; F, female; Fr, frontal; I, insula; L, left; Lt, lateral temporal; M, male; max T/C, maximal tumour-to-contralateral homotopic ratio; mean T/C, mean tumor-to-contralateral homotopic ratio; MET-PET, [11C]-methionine positron emission tomography; mT, mesial temporal; MRI, magnetic resonance imaging; NA, not available; O, occipital; OR, tumour-to-contralateral occipital ratio; P, parietal; R, right. | ||||||||||||||
1 | M | 24 | 21 | 3 | lT | R | + | 26 | Normal | 0.95 | 1.15 | 0.94 | TTV | DNT |
2 | F | 24 | 19 | 5 | lT | R | + | 32 | Marked | 1.95 | 2.7 | 1.89 | TTV | Pleomorphic Xanthoastrocytoma II |
3 | M | 32 | 25 | 7 | I + Fr + P | R | + | 54 | Marked | NA | 5.8 | 2.7 | TTV | Oligodendroglioma III |
4 | F | 18 | 13 | 5 | mT | L | + | 20 | Normal | NA | NA | NA | TTV | DNT |
5 | M | 31 | 14 | 17 | mT | L | – | 13 | Normal | 0.63 | 0.66 | 0.44 | TTV | DNT |
6 | F | 46 | 34 | 12 | Fr + T | R | – | 53 | Marked | NA | 3.63 | 1.86 | TTV | Oligodendroglioma III |
7 | M | 22 | 10 | 12 | mT | R | – | 30 | Normal | NA | NA | NA | TTV | DNT |
8 | M | 56 | 50 | 6 | O + lT | L | – | 62 | Marked | 1.53 | 2.93 | 1.62 | TTV | Oligodendroglioma III |
9 | F | 13 | 10 | 3 | mT | R | + | 28 | Moderate | 1.25 | 1.76 | 0.85 | TTV | Ganglioglioma |
10 | M | 23 | 3 | 20 | O | L | NA | 35 | Marked | NA | 2.25 | 1.14 | TTV | Ganglioglioma |
11 | M | 19 | 17 | 2.5 | Fr | L + R | + | 33 | Marked | 1.78 | 1.9 | 1.83 | TTV | Pilocytic Astrocytoma I |
12 | M | 12 | 10 | 2 | mT | R | + | 22 | Moderate | 1.74 | 2.2 | 1.1 | HR+ | Ganglioglioma |
13 | F | 42 | 37 | 5 | mT | L | – | 25 | Normal | 1.04 | 1.3 | 0.88 | HR+ | DNT |
14 | F | 10 | 7 | 3 | O + lT | L | – | 35 | Moderate | 0.91 | 1.7 | 1.05 | HR+ | DNT |
15 | F | 16 | 2 | 14 | mT | R | + | 19 | Moderate | 2.04 | 2.33 | 1.35 | HR+ | Ganglioglioma |
16 | F | 44 | 1 | 43 | O + lT | R | – | 28 | Moderate | 1.30 | 1.76 | 1.16 | HR+ | Ganglioglioma |
17 | F | 8 | 1 | 7 | T + Fr | L | – | 62 | Moderate | NA | 1.64 | 0.85 | HR+ | Oligodendroglioma II |
18 | M | 40 | 25 | 15 | Fr | R | – | 51 | Marked | 1.70 | 3.37 | 2.35 | HR+ | Oligodendroglioma II |
19 | F | 46 | 30 | 6 | P | L | – | 43 | Moderate | 1.22 | 1.7 | 1.07 | HR+ | DNT |
20 | M | 32 | 18 | 14 | mT | L | – | 31 | Normal | 1.17 | 1.07 | 0.81 | HR+ | DNT |
21 | F | 27 | 25 | 1.5 | lT | L | NA | 27 | Moderate | NA | 1.88 | 1.19 | HR+ | DNT |
22 | M | 43 | 42 | 1.5 | mT | R | – | 32 | Marked | 1.42 | 3.11 | 1.9 | HR+ | Astrocytoma III |
23 | M | 26 | 26 | 8 months | I + Fr + T | R | – | 69 | Moderate | 1.28 | 2.9 | 1.31 | HR+ | Oligoastrocytoma II |
24 | F | 18 | 8 | 10 | lT + mT | L | – | 29 | Moderate | 1.06 | 1.7 | 1.2 | HR+ | DNT |
25 | M | 42 | 33 | 9 | Fr | R | – | 38 | Moderate | 1.66 | 2.01 | 1.23 | HR+ | Oligoastrocytoma II |
26 | M | 27 | 18 | 9 | mT | L | + | 22 | Normal | 1.24 | 1.19 | 0.65 | HR+ | DNT |
27 | M | 41 | 35 | 6 | O + lT | L | + | 48 | Marked | 2.27 | 3.37 | 2.32 | HR+ | Oligodendroglioma II |